ATE499115T1 - Antikörper verwiesene enzymprodrugtherapie mit glukuronidase - Google Patents
Antikörper verwiesene enzymprodrugtherapie mit glukuronidaseInfo
- Publication number
- ATE499115T1 ATE499115T1 AT99948261T AT99948261T ATE499115T1 AT E499115 T1 ATE499115 T1 AT E499115T1 AT 99948261 T AT99948261 T AT 99948261T AT 99948261 T AT99948261 T AT 99948261T AT E499115 T1 ATE499115 T1 AT E499115T1
- Authority
- AT
- Austria
- Prior art keywords
- target site
- drug
- enzyme
- glucuronidase
- pretargeting
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title abstract 4
- 108090000790 Enzymes Proteins 0.000 title abstract 4
- 229940002612 prodrug Drugs 0.000 title abstract 3
- 239000000651 prodrug Substances 0.000 title abstract 3
- 102000053187 Glucuronidase Human genes 0.000 title 1
- 108010060309 Glucuronidase Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 3
- 239000002254 cytotoxic agent Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 231100000419 toxicity Toxicity 0.000 abstract 2
- 230000001988 toxicity Effects 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10103998P | 1998-09-18 | 1998-09-18 | |
| PCT/US1999/021308 WO2000016808A2 (en) | 1998-09-18 | 1999-09-17 | Antibody directed enzyme prodrug therapy (edept) with glucoronidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE499115T1 true ATE499115T1 (de) | 2011-03-15 |
Family
ID=22282805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99948261T ATE499115T1 (de) | 1998-09-18 | 1999-09-17 | Antikörper verwiesene enzymprodrugtherapie mit glukuronidase |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1113819B1 (de) |
| JP (1) | JP4616991B2 (de) |
| AT (1) | ATE499115T1 (de) |
| AU (1) | AU763628B2 (de) |
| CA (1) | CA2344440A1 (de) |
| DE (1) | DE69943219D1 (de) |
| WO (1) | WO2000016808A2 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7833528B2 (en) | 1998-06-22 | 2010-11-16 | Immunomedics, Inc. | Use of multispecific, non-covalent complexes for targeted delivery of therapeutics |
| EP1560596A1 (de) * | 2002-11-15 | 2005-08-10 | Immunomedics, Inc. | Verwendung von multispezifischen, nicht-kovalenten komplexen für die gezielte abgabe von therapeutika |
| MXPA05008222A (es) * | 2003-01-31 | 2005-10-05 | Immunomedics Inc | Metodos y composiciones para administrar agentes terapeuticos y de diagnostico. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ225599A (en) * | 1987-08-04 | 1991-09-25 | Bristol Myers Co | Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells |
| US5851527A (en) * | 1988-04-18 | 1998-12-22 | Immunomedics, Inc. | Method for antibody targeting of therapeutic agents |
| DE4106389A1 (de) * | 1991-02-28 | 1992-09-03 | Behringwerke Ag | Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung |
| CA2069439A1 (en) * | 1989-12-15 | 1991-06-16 | Susumu Iwasa | Monoclonal antibodies, their production and use |
| RU2189251C2 (ru) * | 1994-12-23 | 2002-09-20 | Зенека Лимитед | Химические соединения |
| GB9524942D0 (en) * | 1995-12-06 | 1996-02-07 | Aepact Ltd | Drug therapy |
| EP0954340B1 (de) * | 1996-05-03 | 2007-06-27 | Immunomedics, Inc. | Zielgerichtete kombinations-immuntherapie für krebs |
| JP2002504340A (ja) * | 1998-02-19 | 2002-02-12 | セイント．ジュード チルドレンズ リサーチ ホスピタル | ヒト腫瘍細胞類を感作しおよびヒト腫瘍細胞の増殖を阻害するための組成物および方法 |
| US7074405B1 (en) * | 1998-06-22 | 2006-07-11 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
-
1999
- 1999-09-17 AT AT99948261T patent/ATE499115T1/de not_active IP Right Cessation
- 1999-09-17 CA CA002344440A patent/CA2344440A1/en not_active Abandoned
- 1999-09-17 DE DE69943219T patent/DE69943219D1/de not_active Expired - Lifetime
- 1999-09-17 WO PCT/US1999/021308 patent/WO2000016808A2/en not_active Ceased
- 1999-09-17 EP EP99948261A patent/EP1113819B1/de not_active Expired - Lifetime
- 1999-09-17 AU AU61475/99A patent/AU763628B2/en not_active Ceased
- 1999-09-17 JP JP2000573769A patent/JP4616991B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU6147599A (en) | 2000-04-10 |
| WO2000016808A3 (en) | 2000-09-28 |
| EP1113819B1 (de) | 2011-02-23 |
| AU763628B2 (en) | 2003-07-31 |
| EP1113819A2 (de) | 2001-07-11 |
| JP4616991B2 (ja) | 2011-01-19 |
| WO2000016808A2 (en) | 2000-03-30 |
| CA2344440A1 (en) | 2000-03-30 |
| DE69943219D1 (de) | 2011-04-07 |
| JP2002526457A (ja) | 2002-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0330201A3 (de) | Methode zur Verbesserung der Aktivität von cytotoxischen Verbindungen | |
| ATE517125T1 (de) | ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN | |
| WO1994004702A3 (en) | Improved detection and therapy of lesions with biotin/avidin conjugates | |
| WO2002038190A3 (en) | Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates | |
| SE8202172L (sv) | Topiska farmaceutiska kompositioner | |
| ES2190075T3 (es) | Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico. | |
| BR9303469A (pt) | Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas | |
| AU7001001A (en) | Modified forms of pharmacologically active agents and uses therefor | |
| ATE81986T1 (de) | Wirkstoff - monoklonale antikoerper - konjugate. | |
| ES2102196T3 (es) | Periferializacion de celulas pluripotenciales hematopoyeticas. | |
| ATE245662T1 (de) | Avidin-biotin immunokonjugate | |
| PL322015A1 (en) | Derivatives of hydroxylamine useful as compounds enhancing production of accompanying molecular protein and ethod of obtaining them | |
| HUP0004349A2 (hu) | Vegyületek női szexuális diszfunkció kezelésére | |
| ES2243229T3 (es) | Formulaciones de particulas de hidrogel. | |
| BR9406514A (pt) | Composições terapeuticas de nadh e nadh estáveis que podem ser ingeridas e absorvidas | |
| GB9415167D0 (en) | Improvements relating to cancer therapy | |
| DE69826684D1 (de) | Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendungen | |
| NO944838L (no) | Arabinogalaktanderivater og anvendelser derav | |
| IT1264530B (it) | Impiego dei polisaccaridi nelle neuropatie atrofico degenerative | |
| DK324185D0 (da) | 2-substituerede 1,3-propylidendiphosphonatderivater, deres fremstilling og farmaceutiske praeparater med indhold deraf | |
| FI891718A0 (fi) | Foerfarande foer att befria cellblandningar och vaevnader av icke-oenskade populationer. | |
| ATE499115T1 (de) | Antikörper verwiesene enzymprodrugtherapie mit glukuronidase | |
| DK0484112T3 (da) | Anvendelse af lithium ved behandlingen eller profylakse af Molluscum contagiosum | |
| DE69612056D1 (de) | Terpenderivate (sarcodictyine) als antikrebsmittel | |
| EP1023901A4 (de) | Heilmittel für hepatitis c und dessen verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |